Advertisement Kyowa Hakko Kirin to consolidate and reorganize research and development divisions - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Kyowa Hakko Kirin to consolidate and reorganize research and development divisions

Kyowa Hakko Kirin has announced that it would consolidate and reorganize the research and development divisions, effective April 1 2014.

After the consolidation, the new division will be called the R&D division. The purposes of the reorganization are to advance Kyowa Hakko Kirin’s ‘category-based strategy’ and enhance the productivity of its R&D activities.

Kyowa Hakko Kirin will implement the following measures in the new division:

– Integrate operations of drug discovery research, project management of development products and value creation research of launched products in each category-based R&D unit.

– Speed up R&D through close collaboration between category-based units and three core functions units corresponding to research technology platform, translational research (TR), and development operation, respectively.

– Enhancing drug discovery and preclinical research through open innovation style utilizing external opportunities.

Within the R&D Division, there will be R&D units for four therapeutic categories that will develop R&D plans and implement these plans for the enhancement of product pipeline in each category.

In addition to these category-based R&D units, three function-based units will be formed: the Research Functions unit, the TR unit, and the Development Functions unit.

Besides the above mentioned units, there will also be the R&D Planning Department, the Open Innovation Department, Fuji Research Park and Tokyo Research Park. Please refer to the organizational chart below for more details.